<DOC>
	<DOCNO>NCT01328886</DOCNO>
	<brief_summary>The purpose extension study ass long-term safety tolerability omalizumab add-on therapy Japanese pediatric patient ( 6 15 year age ) inadequately control allergic asthma despite current recommend treatment provide continued treatment omalizumab patient previously complete core study .</brief_summary>
	<brief_title>Long-term Safety , Tolerability Efficacy Omalizumab Japanese Children</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Patients complete core study ( IGE025B1301 ) investigator 's clinical judgment could benefit continuous treatment study drug . Patients currently diagnose cancer , currently investigate possible cancer history cancer . Women childbearing potential , defined woman physiologically capable become pregnant , UNLESS : woman whose career , lifestyle , sexual orientation precludes intercourse male partner ; woman whose partner sterilize vasectomy mean ; use highly effective method birth control ; agree total abstinence investigator also judge age , career lifestyle sexual orientation patient ensure compliance . With clinically significant uncontrolled systemic disease ( eg : infection , hematological disease , renal , hepatic , coronary heart disease cardiovascular disease , cerebrovascular , endocrinologic gastrointestinal disease ) treatment period core study . Patients history major protocol violation core study consider potentially unreliable judge investigator site .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>omalizumab</keyword>
	<keyword>allergic asthma</keyword>
	<keyword>pediatric patient</keyword>
</DOC>